TECNOLOGÍA PARA LA MONITORIZACIÓN Y CONTROL DE LA DIABETES

VolverVolver

Resultados 121 resultados LastUpdate Última actualización 29/03/2020 [16:30:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 5 nextPage   por página


SAFE INSULIN PEN NEEDLE

NºPublicación: EP3626290A1 25/03/2020

Solicitante:

PROMISEMED HANGZHOU MEDITECH CO LTD [CN]

WO_2019218650_PA

Resumen de: EP3626290A1

The invention relates to the technical field of a medical device, in particular to a safe insulin pen needle for injecting insulin. The safe insulin pen needle having the above structure effectively circumvents the risk of the needle head protection failure caused by the rotation of the insulin pen during the needle pulling process by some users through a first check flange on one side of a first initial fixing position matched with a first elastic clamping jaw; effectively circumvents the safety risk that the needle tail tends to damage the user through the needle tail protection structure; at the same time, effectively circumvents the risk that the needle tail protector will rotate and thus the needle tail protection will fail during the separation of the insulin pen from the insulin pen needle through a second check flange on one side of a second initial fixing position matched with a second elastic clamping jaw.

traducir

Tracking changes in average glycemia in diabetics

NºPublicación: AU2020201546A1 19/03/2020

Solicitante:

UNIV VIRGINIA PATENT FOUNDATION

US_2019318801_A1

Resumen de: AU2020201546A1

A method, system and computer readable medium for tracking changes in average glycemia in diabetes is based on a conceptually new approach to the retrieval of SMBG data. Using the understanding of HbAlc fluctuation as the measurable effect of the action of an underlying dynamical system, SMBG provides occasional glimpses at the state of this system and, using these measurements, the hidden underlying system trajectory can be reconstructed for individual diabetes patients. Using compartmental modeling a new two-step algorithm is provided that includes: (i) real- time estimate of HbAlc from fasting glucose readings, updated with any new incoming fasting SMBG data point(s), and (ii) initialization and calibration of the estimated HbAlc trace with daily SMBG profiles obtained periodically. The estimation of these profiles includes a factorial model capturing daily BG variability within two latent factors.

traducir

MULTIPLE SENSOR GLUCOSE CONCENTRATION DETERMINATION ANALYZER APPARATUS AND METHOD OF USE THEREOF

NºPublicación: US2020085352A1 19/03/2020

Solicitante:

SANYAL ALODEEP [US]
MBOUOMBOUO BENJAMIN [US]
ABUL HAJ ROXANNE [US]
ABUL HAJ ALAN [US]
SLAWINSKI CHRISTOPHER [US]
HAZEN KEVIN [US]

Resumen de: US2020085352A1

The invention comprises a method and apparatus for noninvasively determining state of a person, comprising the steps of: providing an analyzer comprising a first and second spectrometer unit and a main controller subsystem; replaceably attaching the first spectrometer unit to the person at a first illumination zone; the first spectrometer unit delivering first photons, from first illumination optics, along a first mean z-axis optical path normal to a first x/y-plane tangentially contacting the first illumination zone of the person; replaceably attaching a second spectrometer unit to the person at a second illumination zone; the second spectrometer delivering second photons, from second illumination optics, along a second mean z-axis optical path perpendicular to a second x/y-plane tangentially contacting the second illumination zone of the skin, the first x/y-plane noncoplanar with the second x/y-plane; and the main controller processing detected signals to generate at least one measure of state of the person.

traducir

GLUCOSE OXIDASE-NANOPARTICLE BIOCONJUGATES FOR CANCER TREATMENT AND USES THEREOF

NºPublicación: US2020085966A1 19/03/2020

Solicitante:

UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION [US]

WO_2018218097_A1

Resumen de: US2020085966A1

Bioconjugates and methods of making bioconjugates are provided, wherein the bioconjugates comprise glucose oxidase and nanoparticles that can kill tumor cells. For example, glucose oxidase-iron oxide bioconjugates can produce reactive oxygen species from blood glucose, causing cell death. The use of superparamagnetic iron oxide nanoparticles can provide magnetic resonance imaging guidance to facilitate imaging-guided drug delivery and combine diagnostics with therapy.

traducir

PORTAL SYSTEM-BASED BIONIC PANCREAS

NºPublicación: US2020086048A1 19/03/2020

Solicitante:

IBM [US]

US_2018050154_PA

Resumen de: US2020086048A1

Embodiments include methods and systems for maintaining glucose homeostasis. Systems can include a pump, a first reservoir including a homeostasis agent, an umbilical catheter capable of being advanced in the umbilical vein or in the falciform ligament, and a sensor. Systems can also include a biocompatible coating, a microprocessor in communication with the pump and the sensor, and a power supply. Methods can include implanting a pump and reservoir subcutaneously in a patient, advancing a catheter in the umbilical vein or in the falciform ligament, measuring a blood glucose level, pumping a homeostasis agent, and administering the homeostasis agent to the portal venous system.

traducir

METHOD AND DEVICE UTILIZING MEDICAMENT DELIVERY PROTOCOLS

NºPublicación: US2020086043A1 19/03/2020

Solicitante:

TANDEM DIABETES CARE INC [US]

US_2017165416_A1

Resumen de: US2020086043A1

A device for infusing liquid medicaments such as insulin includes an infusion pump. The device can modify a medicament delivery protocol stored in memory to delivery an alternative medicament delivery protocol with the pump.

traducir

CHEMICAL ABLATION AND METHOD OF TREATMENT FOR VARIOUS DISEASES

NºPublicación: US2020086093A1 19/03/2020

Solicitante:

NEUROTRONIC INC [US]

Resumen de: US2020086093A1

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, nonalcoholic fatty liver disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

traducir

GLOVE

NºPublicación: US2020085373A1 19/03/2020

Solicitante:

THE AGA KHAN UNIV [PK]

Resumen de: US2020085373A1

A glove is described to simultaneously, non-invasively, and continuously, over a period of time, monitor physiological parameters (e.g., blood pressure, blood glucose, oxygen saturation level, electrical activity of the heart, and/or heart rate) of a patient. A computing server that is either communicatively coupled to the glove or is a part of the glove uses the monitored physiological parameters to determine whether the patient has a physiological condition (e.g., hypotension, hypertension, hypoglycemia, hyperglycemia, hypoxia, hyperoxia, arrhythmia, a strong form of tachycardia, a mild form of tachycardia, and/or bradycardia). Related apparatuses, systems, methods, techniques and articles are also described.

traducir

ANALYTE SENSOR

NºPublicación: US2020085350A1 19/03/2020

Solicitante:

DEXCOM INC [US]

US_2020085351_A1

Resumen de: US2020085350A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

traducir

ANALYTE SENSOR

NºPublicación: US2020085351A1 19/03/2020

Solicitante:

DEXCOM INC [US]

US_2020085350_A1

Resumen de: US2020085351A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

traducir

BIOSENSOR CALIBRATION STRUCTURE CONTAINING DIFFERENT SENSING SURFACE AREA

NºPublicación: US2020077956A1 12/03/2020

Solicitante:

IBM [US]

US_2018252662_A1

Resumen de: US2020077956A1

A biosensor calibration structure is provided that includes at least two electrode structures in which at least one of the electrode structures has a non-random nanopattern on the sensing surface which provides a different sensing surface area than at least one other electrode structure. The at least one other electrode structure may be non-patterned (i.e., flat) or have another non-random nanopattern on the sensing surface. A biological functionalization material such as, for example, glucose oxidase or glucose dehydrogenase, can be located on at least the sensing surface of each electrode structure. The biosensor calibration structure can be used within a biosensor calibration method.

traducir

APPARATUS, SYSTEMS, AND METHODS FOR DETERMINING AND DISPLAYING PRE-EVENT AND POST-EVENT ANALYTE CONCENTRATION LEVELS

NºPublicación: US2020077933A1 12/03/2020

Solicitante:

ASCENSIA DIABETES CARE HOLDINGS AG [CH]

US_2019076072_A1

Resumen de: US2020077933A1

Embodiments of the invention provide apparatus, systems, and methods wherein pre-event and post-event analyte concentration readings associated with an event are collected and processed to determine a numerical delta. The numerical delta may be displayed on a visual display to aid in a ready determination of the affect that the event (alone or in combination with medication and/or insulin dosages) had on the analyte concentration levels. Medication and/or insulin dosages may be displayed alongside the numerical delta to gauge immediate relationships between numerical delta, dosage, and/or an associated event. Apparatus and systems for calculating and displaying the numerical delta are described, as are other aspects.

traducir

SYSTEMS AND METHODS FOR ALERTING A USER TO DETECTED EFFECTS OF A RECENT THERAPY ADJUSTMENT

NºPublicación: US2020077960A1 12/03/2020

Solicitante:

MEDTRONIC MINIMED INC [US]

Resumen de: US2020077960A1

A method for confirming effectiveness of therapy provided by an insulin infusion system comprising a computing device communicatively coupled to an insulin delivery pump and a blood glucose sensor, is provided. In response to a corrective action for a detected abnormality in a blood glucose level of a patient, the method monitors a sequence of blood glucose levels of the patient, following the corrective action, by the computing device via the blood glucose sensor; detects an indication that the corrective action is effective to correct the abnormality, by the computing device, wherein the indication comprises a change of direction in the sequence of blood glucose levels, wherein a first trend in the sequence of blood glucose levels shifts at the indication to create a second trend in blood glucose levels, the second trend progressing in an opposite direction of the first trend; and initiates presentation of an alert in response to the detected indication, by the computing device via a communicatively coupled display device.

traducir

ANALYTE SENSOR

NºPublicación: US2020077928A1 12/03/2020

Solicitante:

DEXCOM INC [US]

US_2014257065_A1

Resumen de: US2020077928A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

traducir

Model-Based Personalization Scheme of an Artificial Pancreas for Type I Diabetes Applications

NºPublicación: US2020078516A1 12/03/2020

Solicitante:

UNIV CALIFORNIA [US]

JP_2019055258_A

Resumen de: US2020078516A1

A model-based control scheme consisting of either a proportional-integral-derivative (IMC-PID) controller or a model predictive controller (MPC), with an insulin feedback (IFB) scheme personalized based on a priori subject characteristics and comprising a lower order control-relevant model to obtain PID or MPC controller for artificial pancreas (AP) applications.

traducir

Forecasting blood glucose concentration

NºPublicación: US2020077931A1 12/03/2020

Solicitante:

ONE DROP [US]

WO_2020051101_A1

Resumen de: US2020077931A1

A method, a system and a computer program product for forecasting blood glucose concentration. One or more features for training a blood glucose concentration forecasting model are determined. The features are determined based on one or more input data parameters associated with a user in a plurality of users. Using the determined one or more features, the blood glucose concentration forecasting model is trained. Using the trained blood glucose concentration forecasting model, one or more expected blood glucose concentrations for the user are generated.

traducir

SYSTEM AND/OR METHOD FOR GLUCOSE SENSOR CALIBRATION

NºPublicación: US2020078517A1 12/03/2020

Solicitante:

MEDTRONIC MINIMED INC [US]

US_2017224919_PA

Resumen de: US2020078517A1

The subject matter disclosed herein relates to systems, methods and/or devices for calibrating sensor data to be used in estimating a blood glucose concentration. A relationship between sensor measurements and reference readings may be used to estimate a relationship between sensor measurements and blood glucose concentration. Such sensor measurements may be weighted according to a decreasing function of uncertainty associated with sensor values.

traducir

FOLDOVER SENSORS AND METHODS FOR MAKING AND USING THEM

NºPublicación: US2020077930A1 12/03/2020

Solicitante:

MEDTRONIC MINIMED INC [US]

US_2017055892_A1

Resumen de: US2020077930A1

The invention disclosed herein includes sensors having three dimensional configurations that allow expansive “360°” sensing (i.e. sensing analyte from multiple directions) in the environments in which such sensors are disposed. Embodiments of the invention provide analyte sensors having foldable substrates adapted to produce optimized configurations of electrode elements as well as methods for making and using such sensors. Typical embodiments of the invention include glucose sensors used in the management of diabetes.

traducir

BLOOD GLUCOSE MEASUREMENT DEVICE AND BLOOD GLUCOSE MEASUREMENT SYSTEM USING SAME

NºPublicación: WO2020050433A1 12/03/2020

Solicitante:

UNIV KWANGWOON IND ACAD COLLAB [KR]

Resumen de: WO2020050433A1

The present invention relates to: a blood glucose measurement device, which is a non-invasive blood glucose measurement device that measures blood glucose using sweat rather than blood, and is equipped with a sweat inducing means that does not require a drug during a sweat inducing process; and a blood glucose measurement system using same. The present invention provides a blood glucose measurement device and a blood glucose measurement system using same, wherein the blood glucose measurement device comprises: a sweat inducing unit having two electrodes which are disposed to be spaced apart from each other and to which opposite polarities are applied; a housing for fixing the sweat inducing unit such that the two electrodes are exposed on one surface thereof; and a blood glucose sensor which is inserted into the housing and comes into contact with bodily fluid produced by the sweat inducing unit. Thus, the blood glucose measurement device does not cause problems, such as pain, infection, and scarring, that can be caused by needles, and does not use drugs that can affect the normal sweat secretion activity structure of the skin, and thus does not have any aftereffects for the skin. Even if the amount of sweat secreted is small, the sweat is efficiently collected so that all of the collected sweat can be used for blood glucose measurement, making highly accurate blood glucose measurements possible. The present invention therefore has the effect in which frequent blood glucose m

traducir

ANALYTE SENSOR

NºPublicación: US2020077932A1 12/03/2020

Solicitante:

DEXCOM INC [US]

US_2020085351_A1

Resumen de: US2020077932A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

traducir

Data backfilling for continuous glucose monitoring

NºPublicación: AU2020201259A1 12/03/2020

Solicitante:

DEXCOM INC [US]

AU_2016370177_A1

Resumen de: AU2020201259A1

Methods and apparatus, including computer program products, are provided for backfilling. In some example embodiments, there is provided a method that includes receiving, at a receiver, backfill data representative of sensor data stored, at a continuous blood glucose sensor and transmitter assembly, due to a loss of a wireless link between the receiver and the continuous blood glucose sensor and transmitter assembly; generating, at the receiver, at least one of a notification or a graphically distinct indicator for presentation at a display of the receiver, the at least one of the notification or the graphically distinct indicator enabling the backfill data to be graphically distinguished, when presented at the display, from non-backfill data; and generating, at the receiver, a view including the backfill data, the non-backfill data, and the generated at least one of the notification or the graphically distinct indicator. Related systems, methods, and articles of manufacture are also described. - -- -- - -. -- ---- /) z

traducir

METHODS FOR DELIVERING INSULIN PREPARATIONS INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE

NºPublicación: US2020078311A1 12/03/2020

Solicitante:

RANI THERAPEUTICS LLC [US]

US_2018221287_A1

Resumen de: US2020078311A1

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

traducir

CLOSED LOOP CONTROL OF PHYSIOLOGICAL GLUCOSE

NºPublicación: EP3618713A1 11/03/2020

Solicitante:

LILLY CO ELI [US]

CN_110582231_A

Resumen de: WO2018204568A1

The present disclosure relates to systems and methods for controlling physiological glucose concentrations in a patient using a closed loop artificial pancreas. The systems and methods may utilize a controller with control logic operative to execute a multi-model predictive controller algorithm to determine a medication dose to the patient.

traducir

FILTER FOR REDUCING PHENOLIC COMPOUNDS FROM INSULIN AND RELATED INFUSION AND INJECTION DEVICES

NºPublicación: EP3618890A1 11/03/2020

Solicitante:

BECTON DICKINSON CO [US]

CN_110582313_A

Resumen de: WO2018204327A1

FILTER FOR REDUCING PHENOLIC COMPOUNDS FROM INSULIN AND RELATED INFUSION AND INJECTION DEVICES Provided herein are devices, systems, and methods for the removal of preservatives/excipients/stabilizers from pharmaceutical preparations/medicaments. The devices and systems include a resin for the filtering of preservatives from pharmaceutical preparations. The methods allow for a period of time of incubation of the pharmaceutical preparation in the resin that effectively removes preservatives, while at the same time maintaining the required amount or concentration of active compound in the preparation. Also provided herein are devices, systems, and methods for the controlled release of anti-inflammatory agents in an insulin infusion set.

traducir

METHODS FOR REDUCTION OF BATTERY USAGE IN AMBULATORY INFUSION PUMPS

Nº publicación: US2020077340A1 05/03/2020

Solicitante:

TANDEM DIABETES CARE INC [US]

US_2017142658_PA

Resumen de: US2020077340A1

A battery-powered infusion pump for delivery of insulin or other medicament may collect and store data related to the pump. The infusion pump can communicate some or all of the stored data to another device, and control the timing and amount of data communicated in order to conserve battery life.

traducir

Página1 de 5 nextPage por página

punteroimgVolver